Home

overview

This activity is designed to help clinicians bridge key gaps in inflammatory bowel disease (IBD) management. Learners will gain a better understanding of the rapidly evolving IBD therapies and the nuances among agents targeting the same pathway. By the end of this program, participants will be able to choose the most appropriate interleukin (IL)-23 inhibitor for individual patients—whether biologic-naive or biologic-experienced—using objective remission endpoints and patient-reported outcomes and will have honed a patient-centered care approach that incorporates shared decision-making.

This event is neither sponsored by nor endorsed by ACG.

faculty

MODERATOR

David T. Rubin, MD

Joseph B. Kirsner Professor of Medicine

Chief, Section of Gastroenterology, Hepatology and Nutrition

Director, Inflammatory Bowel Disease Center

University of Chicago Medicine

Chicago, Illinois

PANELIST

Jessica R. Allegretti, MD, MPH, FACG, AGAF

Associate Professor, Medicine

Harvard Medical School

Director, Crohn’s and Colitis Center

Director, Fecal Microbiota Transplant Program

Brigham & Women’s Hospital

Boston, Massachusetts

PANELIST

Jamie T. Brogan, MS, FNP-BC

Northwestern Medicine Digestive Health Institute

Chicago, Illinois

PANELIST

Corey A. Siegel, MD, MS

Constantine and Joyce Hampers Professor of Medicine

Geisel School of Medicine at Dartmouth

Director, Center for Digestive Health

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire

AGENDA

7:00 PM TZ

Registration and Dinner

7:30 PM TZ

Welcome and Introductions

David T. Rubin, MD

7:35 PM TZ

Treat-to-Target in Practice, Part 1

Corey A. Siegel, MD, MS

7:45 PM TZ

Animation: Pathways of IL-23 Inhibition in IBD

Jessica R. Allegretti, MD, MPH, AGAF, FACG

7:50 PM TZ

Exploring Data on IL-23 Inhibitors in IBD

Jessica R. Allegretti, MD, MPH, AGAF, FACG; Jamie T. Brogan, MS, FNP-BC

8:20 PM TZ

Treat-to-Target in Practice, Part 2

Corey A. Siegel, MD, MS; David T. Rubin, MD

8:35 PM TZ

Best Practices in Patient-Centered Care

Corey A. Siegel, MD, MS; David T. Rubin, MD

8:50 PM TZ

Audience Q&A and Panel Discussion

David T. Rubin, MD

TARGET AUDIENCE

This educational activity is intended for an audience of gastroenterologists, nurse practitioners, physician assistants, and nurses in the United States.

GOAL STATEMENT

The goal of this activity is for learners to be better able to select IL-23 inhibitors for IBD based on objective remission endpoints and develop a patient-centered care strategy for individuals with IBD.

LEARNING OBJECTIVES

[bold]Upon completion of this activity, participants will:[/bold] [para]Have increased knowledge regarding the[/para] [list][item]Main signaling pathways involved in the pathophysiology of IBD [item]Differences among IL-23-targeted inhibitors for IBD[/list] [para]Have greater competence related to[/para] [list][item]Selecting IL-23 inhibitors for IBD based on objective remission endpoints [item]Implementing a patient-centered care strategy for individuals with IBD [/list]

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

[title]For Physicians[/title] [text]Medscape, LLC designates this live activity for a maximum of 1.50 [bold][italic]AMA PRA Category 1 Credit(s)[/italic][super]TM[/super][/bold]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.[/text] [break] [title]For Nurses[/title] [text]Awarded 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs.[/text]

Exploring IL-23 Inhibitors for Inflammatory Bowel Disease CME/CNE

overview

This event is neither sponsored by nor endorsed by ACG.

Enhance Your Experience With MedChallenge!

faculty

AGENDA

Registration and Dinner

Welcome and Introductions

Treat-to-Target in Practice, Part 1

Animation: Pathways of IL-23 Inhibition in IBD

Exploring Data on IL-23 Inhibitors in IBD

Treat-to-Target in Practice, Part 2

Best Practices in Patient-Centered Care

Audience Q&A and Panel Discussion

LOCATION

Sheraton Phoenix Downtown

TARGET AUDIENCE

GOAL STATEMENT

LEARNING OBJECTIVES

ACCREDITATION STATEMENT